EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Zevra Therapeutics, Inc.
ZVRA

ZVRA Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. · NASDAQ
Market Closed
11.61
▼ ⁦-1.94%⁩ (-0.23)
Market Cap$686.3M
Beta0.92
52w Low52w High
7.1615.04
Last Week
⁦-3.33%⁩
Last Month
⁦+0.69%⁩
Last 3 Months
⁦+3.94%⁩
Last Year
⁦+30.16%⁩
EL7 Factor Analysis
How we score this
Overall40
Weak — below market medianSuper StockF 6/9SafeBetter than 40% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
73
12.4x▲17.6xTop tier
▸
Growth
97
119.4%▲7.1%Top tier
▸
Quality
91
35.8%▲4.5%Top tier
▸
Safety
88
—2.6xTop tier
▸
Capital Return
90
—2.15%Top tier
▸
Momentum
71
29.3%▲2.3%Top tier
▸
Sentiment
40
7▲3Bottom tier

Frequently Asked Questions

What is Zevra Therapeutics, Inc. stock?▼

Zevra Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Zevra Therapeutics, Inc.?▼

You can buy Zevra Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Zevra Therapeutics, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Zevra Therapeutics, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Zevra Therapeutics, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$12
Analyst target · 6 analysts
$24
—
Range ⁦$20–$35⁩
vs
DCF (estimate)
$14
⁦+18%⁩
Sees it undervalued
⁦8.5⁩% discount · ⁦5⁩% growth

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 6 analysts setting price target
$25.75
⁦+121.8%⁩
Current Price $11.61·Median $24.00
Low
$20.00
High
$35.00
Current price
$11.61
Average target
$25.75
Street summary

Zevra Therapeutics (ZVRA) Price Target Analysis

Bullish tilt

Data has shown complete stability in the average price target for ZVRA at $25.75 over the past thirty days, with a consensus from 6 analysts. Despite this stable average, there is a dispersion in estimates between a low of $20 and a high of $35; however, all these targets remain significantly higher than the current stock price of $11.74, reflecting a substantial positive valuation gap.

As of 2026-08-26
Revisions momentum · 30d
⁦0.0%⁩
Average rating
★ 4.22
Buy
Analyst coverage
9
Buy conviction
100%
High
Target dispersion
129%
Wide
Analyst ratings over time9 analysts rating
2
7
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.22 → 4.22
Recent analyst moves
  • = Reiterate2026-08-20
    UBS
    Buy
  • = Reiterate2026-08-20
    H.C. Wainwright
    Buy
  • = Reiterate2026-08-06
    Citigroup
    Outperform
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    12.35x
    3.85x44.95x
    Cheap
  • Forward P/E
    12.63x
    4.71x37.71x
    Very cheap
  • EV / EBITDA
    6.51x
    3.78x30.25x
    Very cheap
  • FCF Yield
    4.7%
    -139.6%7.8%
    Strong
  • Revenue Growth YoY
    119.4%
    -57.4%93.8%
    Exceptional
  • EPS Growth YoY
    476.0%
    -159.3%129.8%
    Exceptional
  • Gross Margin
    95.0%
    12.8%90.7%
    Exceptional
  • ROIC
    35.8%
    -154.2%16.1%
    Exceptional
  • Net Debt / EBITDA
    —
    —
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    5.28
    -36.5017.81
    Strong
Financial Analysis
|